5th February 2026
Global central banks remain on hold while oil and metals slide. Learn how higher-for-longer rates and falling commodities are driving sector winners and losers.
17th January 2026
Vera’s IgAN drug atacicept earned FDA Priority Review, but a July 7, 2026 PDUFA date signals timeline risk that could impact valuation and cash runway.
17th January 2026
Strive’s merger with Semler quietly shifted a $100M convertible note onto its balance sheet. Here’s why that subtle change matters for risk
17th January 2026
When companies go silent on deal details, should investors worry? Federal Signal’s sparse 8-K shows how material news can hide in plain sight.
17th January 2026
A practical guide to key SEC 8-K Item codes, explaining which filings signal material events and why major disclosures often go unnoticed.
17th January 2026
An investor-friendly explainer of ASC 842 accounting, showing why sale-leasebacks don’t improve balance sheets despite large cash inflows.
17th January 2026
A deep-dive case study on Denny’s overlooked Form 8-K filing, revealing a $145.5M sale-leaseback, delisting timeline, and hidden market signals.